Answers are grounded in this paper and cite their sources.
Conventional microneedle-based transdermal delivery is often limited by passive diffusion or endogenous stimuli, offering poor control over release kinetics and insufficient penetration into deep tissues. Here, we report a fully integrated wearable drug delivery system that couples a flexible and stretchable ultrasound-responsive microneedle patch (Us-MP) with a portable, Bluetooth-programmable ultrasound driver. This platform enables on-demand drug release, with rapid delivery within 10 min or sustained release up to 50 h. Moreover, ultrasound-induced directional acoustic streaming at the microneedle tips significantly enhances transdermal penetration. As a proof of concept, this system enabled precise colchicine delivery, producing rapid anti-inflammatory and anti-swelling effects in acute gouty arthritis, as well as long-term therapeutic and preventive efficacy in chronic gouty arthritis. This work establishes a controllable and versatile strategy for personalized transdermal therapy, with potential applications across diverse diseases and stages of progression.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: